Open in new window
|
|
Pharmaindustrial News
|
|
Sen-Jam Pharmaceutical and KVK-Tech to Provide CMC for Anti-Inflammatory Injectable
Sen-Jam Pharmaceutical has entered a third strategic collaboration with KVK-Tech.
Read more
|
|
|
Vertex Signs Agreement to Acquire Alpine Immune Sciences
Vertex Pharmaceuticals has signed a definitive agreement with Alpine Immune Sciences, a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies.
Read more
|
|
|
Healx Secures Investment Agreement with Children's Tumor Foundation
The agreement entails payments from CTF to support the advancement of Healx's AI-powered neurofibromatosis program, particularly focusing on its lead candidate, HLX-1502, slated to enter a Phase 2...
Read more
|
|
|
Nuevocor Appoints Dr. John Lee as Chief Medical Officer
In response to his appointment, Dr. Lee expressed enthusiasm about joining Nuevocor and leading the clinical development efforts for the LMNA DCM program.
Read more
|
|
|
Dr. Reddys Unveils Drug-Free Migraine Management Device in Europe
Dr. Reddy’s Laboratories Ltd. has introduced the non-invasive migraine management wearable device, Nerivio in Germany through its step-down subsidiary Betapharm.
Read more
|
|
|
Sanofi Receives Nod for IMOVAX-Polio in India
Sanofi has gained approval for IMOVAX-Polio, an alternative injectable vaccine.
Read more
|
|
|
Aptar Pharma Gets NMPA Nod for Airless Drug Delivery System
Aptar Pharma has received approval by the National Medical Products Administration (NMPA) in China of Sinomune Pharmaceutical’s Li Fu metronidazole gel.
Read more
|
|
|
Strides Pharma Receives FDA Approval for Antidepressant Drug
Strides Pharma Science’s subsidiary has gained approval from the US health regulator to market a generic antidepressant medication.
Read more
|
|
Articles
|
|
Empowering Communities with Pharma Sector: Vision and Commitments for World Health Day 2024
World Health Day, commemorated every year on April 7th, underscores the universal importance of health and well-being. As a cornerstone of healthcare, the pharmaceutical...
Read more
|
|
|
|
This message and any attachments are confidential and privileged and intented for the use of the addressee only. If you have received this communication in error, please notify the sender by replay e-mail and delete this message from your system. Please note that Internet e-mail guarantees neither the confidentiality nor the proper receipt of the message sent. The data deriving from our correspondence with you are included in a file of OMNIMEDIA, S.L. which exclusive purpose is to manage the communications of the company; under the understanding that, in maintaining said correspondence, you authorize the treatment of such data for the mentioned purpose. You are entitled to exercise your rights of access, rectification, cancellation and opposition by addressing such written application to address C/ Pollensa, 2, Edif. Artemisa of. 12 de LA ROZAS (28290 - MADRID) enclosing your NIF or identifying document photocopies of.
Unsubscribe
|